A Phase 1, Open-Label Study to Assess the Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With Edematous Fibrosclerotic Panniculopathy
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2018
At a glance
- Drugs Collagenase (Primary)
- Indications Cellulite
- Focus Pharmacokinetics
- Sponsors Endo Pharmaceuticals
- 26 Nov 2018 Status changed from recruiting to completed.
- 09 Oct 2018 Status changed from not yet recruiting to recruiting.
- 22 Sep 2018 New trial record